Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01646320 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT01646320 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 320 participants.
The verdict
NCT01646320, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
Interventions
- DRUG Dapagliflozin
- DRUG Saxagliptin
- DRUG Placebo matching with Dapagliflozin
- DRUG Metformin immediate release (IR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01646320
The ClinicalTrials.gov registry entry for NCT01646320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT01646320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01646320 about?
NCT01646320 is a clinical study titled "Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes". The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be stu...
What is the current status of trial NCT01646320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2012-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01646320?
The interventions under investigation include: Dapagliflozin (DRUG), Saxagliptin (DRUG), Placebo matching with Dapagliflozin (DRUG), Metformin immediate release (IR) (DRUG).
Who is sponsoring clinical trial NCT01646320?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.